{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:48:51Z","timestamp":1792705731957,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Articular involvement is the most common extraintestinal manifestation associated with inflammatory bowel diseases (IBDs). Manifestations are \u2018paradoxical\u2019 when they occur during treatment, notably with anti-tumor necrosis factor (anti-TNF) drugs, which are expected to prevent or treat them. The aim of this study was to assess the frequency, characteristics, and associated factors of paradoxical articular manifestations in patients with IBD treated with anti-TNF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>In this prospective single-center study, an examination by a rheumatologist was systematically offered to all patients with IBD treated with infliximab (IFX) to assess the prevalence of articular manifestations and distinguish between those related to treatment and those associated with intestinal disease. Paradoxical manifestations were defined as the occurrence of articular manifestations (excluding induced lupus and hypersensitivity reactions) during anti-TNF therapy in patients with intestinal remission. Measures of biological inflammatory, immunological markers, HLA-B27 allele, IFX trough levels, and anti-IFX antibody (Ab) were performed for all patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between May 2013 and April 2014, 65 patients with Crohn\u2019s disease and 15 with patients ulcerative colitis treated with IFX were included. The median duration of anti-TNF therapy was 66 months [quartile (Q)1=23 months\u2013Q3=81 months]. Articular manifestations were observed in 50 (62%) patients treated with IFX. Eleven percent (<jats:italic toggle=\"yes\">n<\/jats:italic>=9) were considered to be associated with IBD and 16% (<jats:italic toggle=\"yes\">n<\/jats:italic>=13) to be associated with anti-TNF therapy. Among articular manifestations associated with anti-TNF therapy, nine (11%) patients were considered paradoxical, two (2%) as drug-induced lupus, and two (2%) as a hypersensitivity reaction. Among the nine patients with paradoxical manifestations, all had Crohn\u2019s disease in clinical remission, three patients presented a spondyloarthropathy, and three developed associated paradoxical psoriasis. No patient discontinued anti-TNF because of the articular manifestations. Methotrexate was effective on articular symptoms in two of the three treated patients with paradoxical manifestations. No clinical or biological factors, including IFX trough levels, were associated with the occurrence of paradoxical manifestations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Paradoxical articular manifestations in IBD patients treated by anti-TNF are common, affecting more than 10% of patients. These events are generally mild and do not need discontinuation of anti-TNF therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000000643","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T12:08:26Z","timestamp":1461240506000},"page":"876-881","source":"Crossref","is-referenced-by-count":30,"title":["Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab"],"prefix":"10.1097","volume":"28","author":[{"given":"Henri","family":"Thiebault","sequence":"first","affiliation":[{"name":"Department of Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Boyard-Lasselin","sequence":"additional","affiliation":[{"name":"EA4666, Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Guignant","sequence":"additional","affiliation":[{"name":"EA4666, LNPC, Department of Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Guillaume","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology and Histocompatibility"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Wacrenier","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Department of Digestive and Oncologic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Rebibo","sequence":"additional","affiliation":[{"name":"Department of Digestive and Oncologic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Brazier","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Meynier","sequence":"additional","affiliation":[{"name":"Clinical Research and Innovation Directorate, Amiens University Hospital, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nguyen-Khac","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Dupas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Go\u00ebb","sequence":"additional","affiliation":[{"name":"EA4666, Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","article-title":"Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients","volume":"23","author":"Veloso","year":"1996","journal-title":"J Clin Gastroenterol"},{"key":"R2-20231020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R3-20231020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R4-20231020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.crohns.2009.11.005","article-title":"The joint\u2013gut axis in inflammatory bowel diseases","volume":"4","author":"Brakenhoff","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R5-20231020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"key":"R6-20231020","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1111\/j.1572-0241.2002.06064.x","article-title":"Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn\u2019s disease","volume":"97","author":"Herfarth","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R7-20231020","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00296-004-0467-8","article-title":"The effect of infliximab on extraintestinal manifestations of Crohn\u2019s disease","volume":"25","author":"Kaufman","year":"2005","journal-title":"Rheumatol Int"},{"key":"R8-20231020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M15-0729","article-title":"Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study","volume":"164","author":"Cleynen","year":"2016","journal-title":"Ann Intern Med"},{"key":"R9-20231020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"R10-20231020","first-page":"S11","article-title":"Severe auto-immune driven arthralgia as a new side effect in anti-TNF\u03b1 treated IBD patients?","volume":"4","author":"Van Moerkercke","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R11-20231020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrgastro.2012.125","article-title":"Paradoxical inflammation induced by anti-TNF agents in patients with IBD","volume":"9","author":"Cleynen","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R12-20231020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"R13-20231020","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy","volume":"8","author":"Rahier","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-20231020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R15-20231020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ibd.21362","article-title":"Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-\u03b1 antibody-treated patients with inflammatory bowel disease","volume":"17","author":"Beigel","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R16-20231020","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R17-20231020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: systematic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"Suppl A","key":"R18-20231020","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"R19-20231020","first-page":"326","article-title":"The potential of ESSG spondyloarthropathy classification criteria as a diagnostic aid in rheumatological practice","volume":"29","author":"Gomariz","year":"2002","journal-title":"J Rheumatol"},{"key":"R20-20231020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R21-20231020","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French National Survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R22-20231020","doi-asserted-by":"crossref","first-page":"S-108","DOI":"10.1016\/S0016-5085(15)30371-1","article-title":"Anti-TNF-induced skin manifestations in IBD patients: role for increased drug exposure?","volume":"148","author":"Cleynen","year":"2015","journal-title":"Gastroenterology"},{"key":"R23-20231020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series","volume":"79","author":"Toussirot","year":"2012","journal-title":"Joint Bone Spine"},{"key":"R24-20231020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn\u2019s disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042737-201608000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T05:02:30Z","timestamp":1697778150000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-201608000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000000643","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}